Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 124

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 124
---
xycycline following a tick-bite is a recognized indication to prevent the complications of Lyme disease. There may be more than       
 400,000 such tick bites in the United States requiring medical treatment each year. This estimate is based on the observation that         
 approximately 50,000 tick bites are treated in U.S. hospital emergency rooms each year; however, this calculation represents only          
 about 12% of actual treated tick bites based on observations from comparable ex-U.S health systems.53 Unlike Lyme disease,                 
 there is no characteristic rash associated with early infection and no reliable diagnostic tests. Thus, an individual bitten by a          
 tick cannot know whether they have also been infected with babesiosis. It is likely that a drug proven to be effective for this indication 
 for babesiosis would also be used in conjunction with Lyme prophylaxis.                                                                    |

| ● | Veterinary Indications. Based on estimates from industry experts, there                                                                 
 may be somewhere between several hundred and several thousand cases of canine babesiosis each year in the United States, and thousands  
 more globally. Currently, standard of care treatment for babesiosis in dogs is a ten-day course of atovaquone and azithromycin, which   
 costs about $1,350 out of pocket. A treatment course of Tafenoquine mirroring the human prophylactic dose in dogs might cost <          
 $300, offering a compelling alternative to standard of care. The additional resources required to generate enabling data for veterinary 
 uses are much less expensive than human clinical trials and we are already funding a pilot study at North Carolina State University     
 related to this indication. Separately, the Company is exploring the potential utility of Tafenoquine to manage equine Theileria        
 (a tick-borne disease related to babesiosis). Horses entering the United States are required to be tested prior to quarantine release   
 and treated if positive.                                                                                                                |

Treatment and Prevention of Fungal Infections We are evaluating Tafenoquine for potential utility in the following fungal diseases:

| ● | Treatment                                                                                                                    
 of Candida infections. According to the CDC, there are 50,000 reported cases of candidiasis (a type of fungal infection)     
 each year in the United States and up to 1,900 clinical cases of C. auris, for which there are few available treatments.54   
 Since it has broad-spectrum activity against drug-resistant Candida spp in culture, Tafenoquine, has the potential to        
 be a market leading therapy for treatment